Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25806794 | 0.91 | MAPT (0.44) | CYP3A4KCNH2MAPTRAB9AALDH1A1 | |
| SCHEMBL22045233 | 0.84 | NPC1 (0.50) | MAPTNPC1RAB9AALDH1A1HTT | |
| SCHEMBL21988955 | 0.82 | CYP3A4 (0.53) | CYP3A4KCNH2MAPTNPC1RAB9A | |
| SCHEMBL21988979 | 0.81 | NPC1 (0.47) | MAPTNPC1RAB9AALDH1A1HTT | |
| SCHEMBL22045566 | 0.80 | GRM5 (0.45) | MAPTALDH1A1HTTMAOBSMN1; SMN2 | |
| SCHEMBL21989045 | 0.79 | PLA2G2A (0.43) | CYP3A4KCNH2MAPTNPC1RAB9A | |
| SCHEMBL14699815 | 0.78 | MAPT (0.50) | CYP3A4MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL27213893 | 0.77 | LMNA (0.55) | MAPTNPC1RAB9AALDH1A1HTT | |
| SCHEMBL22045565 | 0.76 | RAB9A (0.44) | CYP3A4MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20201939 | 0.75 | KMT2A (0.56) | CYP3A4MAPTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12103921-B2 | Chemical compounds | PFIZER INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20230382892-A1 | Chemical Compounds | PFIZER INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382892-A1 | Chemical Compounds | PFIZER INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11702405-B2 | Chemical compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702405-B2 | Chemical compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220348555-A1 | Chemical Compounds | PFIZER INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-3886984-A1 | PYRAZOLES AS MODULATORS OF HEMOGLOBIN | Pfizer Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11014908-B2 | Chemical compounds | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014908-B2 | Chemical compounds | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200172512-A1 | Chemical Compounds | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
| WO-2020109994-A1 | PYRAZOLES AS MODULATORS OF HEMOGLOBIN | PFIZER INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020109994-A1 | PYRAZOLES AS MODULATORS OF HEMOGLOBIN | PFIZER INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20200172512-A1 | Chemical Compounds | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172512-A1 | Chemical Compounds | HBZ, HBB, HBS1L | CYP3A4 34/4885KCNH2 1300/4885MAPT 305/4885 |
| US-11702405-B2 | Chemical compounds | HBZ, HBB, HBS1L | CYP3A4 34/4885KCNH2 1300/4885MAPT 305/4885 |
| US-20230382892-A1 | Chemical Compounds | HBZ, HBB, HBS1L | CYP3A4 34/4885KCNH2 1300/4885MAPT 305/4885 |
| US-12103921-B2 | Chemical compounds | HBZ, HBB, HBS1L | CYP3A4 34/4885KCNH2 1300/4885MAPT 305/4885 |
| US-11014908-B2 | Chemical compounds | HBZ, HBB, HBS1L | CYP3A4 34/4885KCNH2 1300/4885MAPT 305/4885 |
| US-20220348555-A1 | Chemical Compounds | HBZ, HBB, HBS1L | CYP3A4 34/4885KCNH2 1300/4885MAPT 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.